Invest $10,000 into these ASX 200 shares in January

Market-beating returns could be on offer from these shares this year according to analysts.

| More on:
View of a business man's hand passing a $100 note to another with a bank in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Do you have $10,000 to invest into ASX 200 shares in January? If you do, then it could be worth considering the two shares in this article.

Let's see why they could be great options for investors this month:

Neuren Pharmaceuticals Ltd (ASX: NEU)

The first ASX 200 share to consider for a $10,000 investment in January is Neuren Pharmaceuticals.

It is a pharmaceuticals company that is focused on developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.

Bell Potter is very bullish on the company. This is partly due to the potential of its NNZ-2591 therapy, which is under development at present. Its analysts said:

Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.

The broker currently has a buy rating and $25.00 price target on its shares. Based on its current share price of $12.20, this implies potential upside of just over 100% for investors between now and this time next year.

Xero Ltd (ASX: XRO)

Another ASX 200 share that could be a good option for a $10,000 investment in January is Xero.

It is a leader in cloud accounting across New Zealand, Australia, and the United Kingdom. Its online accounting software connects small business owners with their numbers, their bank, and advisors at anytime.

Goldman Sachs is a big fan of Xero. This is due to its huge total addressable market (TAM), which gives it a huge growth runway over the coming decades. Goldman highlights that Xero's TAM is over 100 million small to medium sized businesses (SMBs), which compares to its current subscriber base of 4.2 million. The broker said:

Xero is a Global Cloud Accounting SaaS player, with existing focuses in ANZ, UK, North American and SE Asian markets. We see Xero as very well-placed to take advantage of the digitisation of SMBs globally, driven by compelling efficiency benefits and regulatory tailwinds, with >100mn SMBs worldwide representing a >NZ$100bn TAM.

Given the company's pivot to profitable growth and corresponding faster earnings ramp, we see an attractive entry point into a global growth story with Xero our preferred large-cap technology name in ANZ – the stock is Buy rated.

Goldman has a buy rating and $201.00 price target on the company's shares. Based on its current share price of $168.17, this implies potential upside of approximately 20% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Growth Shares

Top brokers name 3 top ASX growth shares to buy now

Why are brokers feeling bullish on these names? Let's find out.

Read more »

Two plants grow in jars filled with coins.
Growth Shares

3 ASX 200 growth stocks up more than 100% in 1 year that could charge higher

It's been a memorable year for shareholders of these 3 companies.

Read more »

Afterpay share price a happy shopper with a wide mouthed smile holds multiple shopping bags up around her shoulders.
Growth Shares

The pros and cons of buying Zip shares in June

Should investors buy now or wait until later?

Read more »

A smiling woman holds a Facebook like sign above her head.
Growth Shares

3 ASX growth shares I'd buy for the next 10 years

Let's see why these shares could be top picks for the long term.

Read more »

wheelchair user in an office talking on mobile phone
Growth Shares

Why I'd buy this ASX growth share instantly

I’m calling on this stock to deliver strong returns.

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
Growth Shares

2 ASX growth shares to buy in June: experts

These businesses have strong growth potential.

Read more »

Rocket powering up and symbolising a rising share price.
Growth Shares

Buy these stellar ASX growth shares with $1,000

Analysts think these shares would be top buys right now.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Growth Shares

These ASX growth shares could rise 18% to 30%

Let's see which shares are being tipped to rocket.

Read more »